RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection.

Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong EHC, Sykes A, Maybeno M, Del Rosario J, Trujillo-Torralbo MB, Mallia P, Sidney J, Peters B, Kon OM, Sette A, Johnston SL, Openshaw PJ, Chiu C. · 2015

Read RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection. by Jozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong EHC, Sykes A, Maybeno M, Del Rosario J, Trujillo-Torralbo MB, Mallia P, Sidney J, Peters B, Kon OM, Sette A, Johnston SL, Openshaw PJ, Chiu C. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4703893.txt.

Introduction

Agnieszka Jozwik, Maximillian S. Habibi, Allan Paras, and a large team studied immune memory against RSV in volunteers, in Nature Communications in 2015. Respiratory syncytial virus is the top cause of severe chest infection in young children, and no vaccine yet exists. Working with adults deliberately infected with the virus, the team tracked virus-specific killer T cells in blood and, by repeated airway sampling, in the lungs themselves. They mapped which virus pieces the cells target and how the cells changed over time.

Lung cells carrying the resident-memory signature piled up to high levels and stayed into recovery. They looked more seasoned but less armed than their blood counterparts. Crucially, people who entered the study with more of these lung cells had milder illness and lower virus levels. The finding suggests lung-resident memory cells guard humans against severe RSV, a target vaccine designers can now aim at.

Catalog record

CREATORJozwik A, Habibi MS, Paras A, Zhu J, Guvenel A, Dhariwal J, Almond M, Wong EHC, Sykes A, Maybeno M, Del Rosario J, Trujillo-Torralbo MB, Mallia P, Sidney J, Peters B, Kon OM, Sette A, Johnston SL, Openshaw PJ, Chiu C.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4703893

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection By Agnieszka Jozwik, Maximillian S Habibi, Allan Paras, Jie Zhu, Aleks Guvenel, Jaideep Dhariwal, Mark Almond, Ernie H C Wong, Annemarie Sykes, Matthew Maybeno, Jerico Del Rosario, Maria-Belen Trujillo-Torralbo Published in: Nature Communications DOI: 10.1038/ncomms10224 ABSTRACT Abstract In animal models, resident memory CD8+ T (Trm) cells assist in respiratory virus elimination but their importance in man has not been determined. Here, using experimental human respiratory syncytial virus (RSV) infection, we investigate systemic and local virus-specific CD8+ T-cell responses in adult volunteers. Having defined the immunodominance hierarchy, we analyse phenotype and function longitudinally in blood and by serial bronchoscopy. Despite rapid clinical recovery, we note surprisingly extensive lower airway inflammation with persistent viral antigen and cellular infiltrates. Pulmonary virus-specific CD8+ T cells display a CD69+CD103+ Trm phenotype and accumulate to strikingly high frequencies into convalescence without continued proliferation. While these have a more highly differentiated phenotype, they express fewer cytotoxicity markers than in blood. Nevertheless, their abundance before infection correlates with reduced symptoms and viral load, implying that CD8+ Trm cells in the human lung can confer protection against severe respiratory viral disease when humoral immunity is overcome. CD8+ T cells are essential effectors that eliminate intracellular pathogens and confer protection against symptomatic reinfection via immune memory1. In animal models of respiratory virus infections such as respiratory syncytial virus (RSV) and influenza, memory CD8+ T cells reduce viral replication, prevent infection or decrease disease severity, and confer cross-protection against antigenically distinct strains2. However, while some vaccine candidates against RSV and influenza may have the capacity to induce CD8+ T cells, they have not yet been shown clinically to improve protection3,4,5. RSV is globally the commonest cause of lower respiratory tract infection in children, leading to an estimated 3.4 million hospitalizations each year6. It is also a major contributor to mortality in older and immunosuppressed adults7. Recurrent symptomatic RSV infection occurs throughout life even with a healthy immune system and limited viral antigenic variation8. Therefore, characterizing immune responses required for robust protection has been problematic and effective vaccines remain a major clinical need2. We recently showed that anti-RSV IgA in the nasal mucosa correlated strongly with protection from infection, but that the high levels required for immunity are poorly maintained, allowing recurrent infection9. Despite this, most older children and young adults suffer only minor symptoms, implying that when antibodies fail to prevent infection, cell-mediated immunity reduces disease severity. In mice, depletion of RSV-specific CD8+ T cells leads to prolonged viral replication, while adoptive transfer of virus-specific memory cells enhances virus clearance10,11. However, the absence of T cells also leads to reduced symptom severity and transfer of RSV-specific memory T cells worsens disease, indicating that harmful immunopathology can outweigh the benefits of cell-mediated viral clearance under certain circumstances12,13. In humans, the role of CD8+ T cells remains less clear with evidence of their protective role mainly limited to observations of children with T-cell defects (who suffer more severe disease with prolonged viral shedding)14. In influenza, correlations between memory T cells in the blood and reduced severity of disease on subsequent infection have been shown15,16, but no such evidence exists in RSV and the extent to which T cells contribute to protection or pathology in this and other respiratory viral infections remains unknown. Respiratory viruses are usually confined to the lung with systemic spread only in the worst cases17. Virus-specific CD8+ T cells in peripheral blood are therefore unlikely in most situations to be directly relevant to protection. Instead, studies of a range of tissues have recently defined a subset of non-circulating memory T cells specialized to protect sites of pathogen entry18. These resident memory T (Trm) cells are not only poised for rapid killing on virus re-encounter but may also exhibit innate-like sensing functions19. In mouse models of influenza, CD4+ and CD8+ Trm cells in the lung confer greater protection than spleen-derived cells20,21. However, restrictions on sampling of human lungs mean that little is known about these Trm cells except that they are abundant in non-inflamed lung from tumour excisions or donated organ tissue22,23. We investigated the CD8+ T-cell response to experimental RSV infection in 49 healthy adult volunteers, around half of who also underwent serial bronchoscopy. While controlled for variations in viral inoculum and co-morbidities, this cohort nevertheless represented a genotypically diverse antigen-experienced population that allowed characterization of the breadth of virus-specific CD8+ T-cell responses and identification of novel immunodominant and subdominant epitopes. Analysis using major histocompatibility complex (MHC)-peptide tetramers revealed highly contrasted kinetics, phenotypes and functionality of RSV-specific CD8+ T cells in the lower respiratory tract compared with blood, the diversity of which allowed us to infer a specialised role in protection against RSV disease. RESULTS Experimental RSV infection causes upper tract disease We enrolled 49 healthy adults aged 18–50 years (median 20.5 years; Supplementary Table 1). Two weeks and immediately before inoculation, they underwent blood and nasal sampling (Fig. 1a). All individuals were then inoculated with 104 plaque-forming units of RSV A Memphis 37 (RSV M37) by intranasal drops as previously described9, followed by sequential blood and nasal samples up to 6 months later. [Figure: Inoculation of healthy adults with RSV causes upper respiratory tract infection.Forty-nine healthy adult volunteers were inoculated with RSV Memphis 37. (a) The study design is shown. (b) Clinical outcomes are shown. (c) Self-reported symptoms scores of 49 subjects were recorded daily. Cumulative data are shown as mean±s.e.m. Infected individuals were defined by having had RSV detected from nasal lavage on at least 2 consecutive days by qPCR of nasal lavage. (d) Symptoms from 49 subjects were categorized as originating from the upper respiratory tract (blue), lower respiratory tract (red) or as systemic (green) according to previously described criteria (see Methods). Data are shown as mean± s.e.m. (e) Viral load of 49 individuals was determined by N gene qPCR from nasal lavage. Individual data points and means are shown.] Twenty-six subjects (53%) developed PCR+ infection (Fig. 1b). Of these, 17 (65%) suffered a ‘common cold' according to standardized criteria (see Methods), while 9 (35%) reported minimal or no symptoms. Symptoms in infected individuals peaked around day 7 post inoculation (Fig. 1c). While almost all symptomatic individuals complained of upper respiratory symptoms, lower respiratory tract and systemic symptoms were unusual (Fig. 1d). In infected individuals, viral load peaked at days 7–8 post infection with a mean of 2.76 log10 copies per ml (±s.e.m. 0.322; Fig. 1e), correlating with self-reported symptoms (Supplementary Fig. 1). RSV causes inflammation in the lower respiratory tract Twenty-four volunteers additionally underwent serial bronchoscopy (Supplementary Table 2). Thus, endobronchial biopsies, bronchial brushings and bronchoalveolar lavage (BAL) were obtained 14 days before inoculation and 7 or 10 and 28 days after. Of these, 50% developed RSV infection. In view of the predominantly upper respiratory disease, we were surprised to find strikingly extensive macroscopic inflammation involving the lower respiratory tract of infected individuals (Fig. 2a; Supplementary Table 3). Lower airways involvement was supported by quantitative PCR (qPCR) of bronchial brushings, which detected RSV in all day 7 samples and 4/5 infected subjects at day 10, again peaking around 7 days (mean 2.22 log10 ml−1±s.e.m. 0.416; Fig. 2b). RSV could also be

Read the complete text